Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling
Copyright © 2024 Elsevier B.V. All rights reserved..
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with high mortality. The Food and Drug Administration-approved drugs, nintedanib and pirfenidone, could delay progressive fibrosis by inhibiting the overactivation of fibroblast, however, there was no significant improvement in patient survival due to low levels of drug accumulation and remodeling of honeycomb cyst and interstitium surrounding the alveoli. Herein, we constructed a dual drug (verteporfin and pirfenidone)-loaded nanoparticle (LipVP) with the function of inhibiting airway epithelium fluidization and fibroblast overactivation to prevent honeycomb cyst and interstitium remodeling. Specifically, Lip@VP extensively accumulated in lung tissues via atomized inhalation. Released verteporfin inhibited the fluidization of airway epithelium and the formation of honeycomb cyst, and pirfenidone inhibited fibroblast overactivation and reduced cytokine secretion that promoted the fluidization of airway epithelium. Our results indicated that Lip@VP successfully rescued lung function through inhibiting honeycomb cyst and interstitium remodeling. This study provided a promising strategy to improve the therapeutic efficacy for IPF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:366 |
|---|---|
| Enthalten in: |
Journal of controlled release : official journal of the Controlled Release Society - 366(2024) vom: 18. Feb., Seite 732-745 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Meng-Meng [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
0X9PA28K43 |
|---|
| Anmerkungen: |
Date Completed 04.03.2024 Date Revised 04.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jconrel.2024.01.032 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367327007 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367327007 | ||
| 003 | DE-627 | ||
| 005 | 20240304232310.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240120s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jconrel.2024.01.032 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1316.xml |
| 035 | |a (DE-627)NLM367327007 | ||
| 035 | |a (NLM)38242209 | ||
| 035 | |a (PII)S0168-3659(24)00044-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Meng-Meng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhaled nanoparticles for treating idiopathic pulmonary fibrosis by inhibiting honeycomb cyst and alveoli interstitium remodeling |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.03.2024 | ||
| 500 | |a Date Revised 04.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with high mortality. The Food and Drug Administration-approved drugs, nintedanib and pirfenidone, could delay progressive fibrosis by inhibiting the overactivation of fibroblast, however, there was no significant improvement in patient survival due to low levels of drug accumulation and remodeling of honeycomb cyst and interstitium surrounding the alveoli. Herein, we constructed a dual drug (verteporfin and pirfenidone)-loaded nanoparticle (LipVP) with the function of inhibiting airway epithelium fluidization and fibroblast overactivation to prevent honeycomb cyst and interstitium remodeling. Specifically, Lip@VP extensively accumulated in lung tissues via atomized inhalation. Released verteporfin inhibited the fluidization of airway epithelium and the formation of honeycomb cyst, and pirfenidone inhibited fibroblast overactivation and reduced cytokine secretion that promoted the fluidization of airway epithelium. Our results indicated that Lip@VP successfully rescued lung function through inhibiting honeycomb cyst and interstitium remodeling. This study provided a promising strategy to improve the therapeutic efficacy for IPF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Airway epithelium | |
| 650 | 4 | |a Fibroblast | |
| 650 | 4 | |a Fluidization | |
| 650 | 4 | |a Idiopathic pulmonary fibrosis | |
| 650 | 4 | |a Inhalation | |
| 650 | 7 | |a Verteporfin |2 NLM | |
| 650 | 7 | |a 0X9PA28K43 |2 NLM | |
| 700 | 1 | |a Tang, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xue-Na |e verfasserin |4 aut | |
| 700 | 1 | |a Fang, Yue-Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Qi, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Bo-Wen |e verfasserin |4 aut | |
| 700 | 1 | |a Yao, Ya-Ting |e verfasserin |4 aut | |
| 700 | 1 | |a He, Yu-Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Xing, Lei |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Hu-Lin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of controlled release : official journal of the Controlled Release Society |d 1996 |g 366(2024) vom: 18. Feb., Seite 732-745 |w (DE-627)NLM085820296 |x 1873-4995 |7 nnns |
| 773 | 1 | 8 | |g volume:366 |g year:2024 |g day:18 |g month:02 |g pages:732-745 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jconrel.2024.01.032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 366 |j 2024 |b 18 |c 02 |h 732-745 | ||